Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation

Dursunoğlu, Dursun; Evrengül, Harun; Polat, Bülent; Tanrıverdi, Halil; Çobankara, Veli; Kaftan, Asuman; Kılıç, Mustafa

doi:10.1007/s00296-004-0438-0

Cited by 133 publications

(104 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…27 In this study we found that patients diagnosed with RA had significantly reduced levels of HDLcholesterol in comparison to control groups. This matched with many other studies done in all of Pakistan 2012, 25 Tunisia 2011, 26 Malaysia 2012, 28 South India, 29 Saudi Arabia 2013, 30 Baghdad, Iraq 2013 31 and the United Kingdom 2011, 32 which is an unfavorable profile about cardiovascular risks 33 and there was no study against it. In this study, we found that there was a statistically significant elevation in all of the serum triglycerideable 2, serum Dyslipidemia has a higher significant prevalence among RA patients in comparison to control groups.…”

Section: P Value Discussionsupporting

confidence: 50%

Prevalence of dyslipidemia and its association with disease activity in patients with rheumatoid arthritis attending Rizgary Teaching Hospital in Erbil City

Hameed¹,

AL-Barzinjy

2017

ZJMS

View full text Add to dashboard Cite

Section: P Value Discussionsupporting

confidence: 50%

Prevalence of dyslipidemia and its association with disease activity in patients with rheumatoid arthritis attending Rizgary Teaching Hospital in Erbil City

Hameed¹,

AL-Barzinjy

2017

ZJMS

View full text Add to dashboard Cite

“…With respect to Lp(a), although there have been numerous reports of elevated levels during acute and chronic inflammation (30), studies examining changes in the level of Lp(a) in association with suppression of inflammation are lacking. Although a recent meta-analysis suggested that Lp(a) is independently associated with an elevated risk of CHD (31), whether Lp(a) is causally linked to CHD is not known.…”

mentioning

confidence: 99%

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double‐blind, placebo‐controlled study

Sattar

Crompton

Cherry

et al. 2007

Arthritis & Rheumatism

110

View full text Add to dashboard Cite

Objective. To conduct a robust, double-blind, placebo-controlled study examining the effects of tumor necrosis factor (TNF) modulation on concentrations of traditional and novel cardiovascular disease risk factors in patients with an inflammatory condition.Methods. In this double-blind study, 127 patients with psoriatic arthritis (PsA) and active psoriasis were randomized to 1 of 3 treatment arms (placebo, onercept 50 mg, or onercept 100 mg for 12 weeks). Traditional and novel biochemical risk factors were evaluated at baseline and at the end of the treatment period.Results. At baseline, an elevated C-reactive protein ( Conclusion. This study is the first to demonstrate that targeting the TNF pathway can significantly decrease Lp(a) and homocysteine levels and elevate Apo A-I and SHBG concentrations. These data support an important precursor role for high-grade inflammation in modulating these putative risk parameters. However, TNF blockade-induced increases in triglyceride and Apo B levels were unexpected and suggest that it is not possible, on the basis of biochemical changes in isolation, to suggest that cardioprotection would necessarily follow; rather, direct measures of atherosclerotic progression with TNF blockade (e.g., using carotid ultrasound) would be better.

show abstract

“…Insulin resistance was observed due to an alleged increase in oxidative stress as well as over expression of pro-inflammatory cytokines [40].…”

Section: Metabolic Abnormalitiesmentioning

confidence: 99%

Co-Morbidity of Cardiovascular Diseases and Rheumatoid Arthritis

Pandya

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic disease related to swelling of joints which lead to restriction in movement due to pain and deformity mainly in feet, ankle, wrist, and fingers. It is an autoimmune disease, and the manifestations caused due to its occurrence are not clearly understood. In today's time, it has been observed that comorbid conditions account for most of the deaths as they influence the outcome of RA and limit therapeutic options. The most common comorbid conditions which are diagnosed in RA patients are generally cardiovascular (CV) abnormalities, several infections, certain mental disorders, and malignancies. Among which CV comorbid diseases are the most common kind relating to disorders of heart and blood vessel that eventually leads to severe conditions such as angina, myocardial infarction, stroke, rheumatic heart disease, and many more. RA affects the quality of life of patients directly or indirectly, but it mainly shows a significant increase in the prevalence of CV diseases. Hence, it is essential to diagnose and understand about the related manifestations when one is suffering from RA. These studies will aid to make better treatment and management strategies. Hence, an attempt has been made in this review article regarding the epidemiology, impact of both diseases and related risk factors. It also gives information in brief about the pathological causes of the comorbidity and summarizes measures that may be used in the prevention and treatment of these conditions.

show abstract

Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation

Abstract: It is suggested that higher serum Lp(a), lower HDL-C, higher TG level, and a high ratio of TC/HDL-C might show high risk of atherosclerosis. Inflammation in RA may cause changes in HDL-C and Lp(a) metabolisms.

Cited by 133 publications

References 28 publications

Prevalence of dyslipidemia and its association with disease activity in patients with rheumatoid arthritis attending Rizgary Teaching Hospital in Erbil City

Prevalence of dyslipidemia and its association with disease activity in patients with rheumatoid arthritis attending Rizgary Teaching Hospital in Erbil City

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double‐blind, placebo‐controlled study

Co-Morbidity of Cardiovascular Diseases and Rheumatoid Arthritis

Contact Info

Product

Resources

About